Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This study found that the Arabidopsis cation chloride cotransporter (CCC1) is crucial for regulating pH and processes in the trans-Golgi-network/early endosome, impacting plant growth and stress responses.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

In this study, topical tacrolimus 0.03% cream showed good to excellent response in treating alopecia areata in 70% of participants, with no cutaneous or systemic side effects observed.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

CTP-543 is generally safe for treating alopecia areata.

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.

This study observed that tributyltin pollution induces imposex, reduces reproductive success, and leads to population decline in Ocinebrina aciculata, highlighting its sensitivity compared to other prosobranch species.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

In this review, researchers summarize the methods for characterizing telocytes, outline their physiological roles and implications in diseases, and discuss potential future studies including precise markers and targeted therapies.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

This observational study reviewed thyroid eye disease patients treated with teprotumumab at one center, reporting common side effects like fatigue and dry eye symptoms, with serious adverse events including two cases of blood clots and one pulmonary embolism.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This study found that tannic acid accelerated wound healing in rats by modulating inflammatory cytokines, increasing growth factors, and activating the Erk 1/2 pathway.

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

This study introduced a simple and reliable in vitro assay capable of large-scale simultaneous screening of hair growth-promoting compounds using a 3D co-culture system of human dermal papilla and outer root sheath cells.